AU2001264012A1 - Novel calcium receptor active molecules and method for preparing same - Google Patents

Novel calcium receptor active molecules and method for preparing same

Info

Publication number
AU2001264012A1
AU2001264012A1 AU2001264012A AU6401201A AU2001264012A1 AU 2001264012 A1 AU2001264012 A1 AU 2001264012A1 AU 2001264012 A AU2001264012 A AU 2001264012A AU 6401201 A AU6401201 A AU 6401201A AU 2001264012 A1 AU2001264012 A1 AU 2001264012A1
Authority
AU
Australia
Prior art keywords
group
chr5
alkyl
aryl
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001264012A
Other languages
English (en)
Inventor
Philippe Marcel Dauban
Robert Dodd
Helene Veronique Faure
Albane Kessler
Pierre Jean-Paul Potier
Martial Ruat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Publication of AU2001264012A1 publication Critical patent/AU2001264012A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
AU2001264012A 2000-05-24 2001-05-23 Novel calcium receptor active molecules and method for preparing same Abandoned AU2001264012A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0006619A FR2809396B1 (fr) 2000-05-24 2000-05-24 Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
FR0006619 2000-05-24
PCT/FR2001/001599 WO2001090069A1 (fr) 2000-05-24 2001-05-23 Composes possedant une activite calcimimetique

Publications (1)

Publication Number Publication Date
AU2001264012A1 true AU2001264012A1 (en) 2001-12-03

Family

ID=8850558

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001264012A Abandoned AU2001264012A1 (en) 2000-05-24 2001-05-23 Novel calcium receptor active molecules and method for preparing same

Country Status (7)

Country Link
US (1) US7084167B2 (fr)
EP (1) EP1284963B1 (fr)
JP (1) JP2003534324A (fr)
AT (1) ATE557002T1 (fr)
AU (1) AU2001264012A1 (fr)
FR (1) FR2809396B1 (fr)
WO (1) WO2001090069A1 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6908935B2 (en) 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
US7176322B2 (en) 2002-05-23 2007-02-13 Amgen Inc. Calcium receptor modulating agents
SI3395339T1 (sl) 2003-09-12 2019-08-30 Amgen, Inc, Hitrotopna formulacija, ki vsebuje cinakalcet HCL
WO2005065050A2 (fr) * 2003-12-25 2005-07-21 Asahi Kasei Pharma Corporation Compose bicyclique
ES2561111T3 (es) * 2004-05-28 2016-02-24 Mitsubishi Tanabe Pharma Corporation Arilalquilaminas y procedimiento para la producción de las mismas
US7361789B1 (en) 2004-07-28 2008-04-22 Amgen Inc. Dihydronaphthalene compounds, compositions, uses thereof, and methods for synthesis
FR2885129B1 (fr) * 2005-04-29 2007-06-15 Proskelia Sas Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation.
EP1965805B1 (fr) * 2005-11-25 2009-12-02 Galapagos SAS Dérivés de l'urée utiles comme modulateurs des récepteurs du calcium
MX2008013339A (es) * 2006-04-20 2009-01-26 Amgen Inc Formulaciones de emulsion estable.
MX2009003981A (es) * 2006-10-26 2009-04-27 Amgen Inc Agentes moduladores del receptor de calcio.
US8093299B2 (en) 2007-03-30 2012-01-10 Amgen Inc. Methods of treating bowel disorders
US8334317B2 (en) * 2007-10-15 2012-12-18 Amgen Inc. Calcium receptor modulating agents
CN102239136B (zh) * 2008-10-03 2014-09-17 味之素株式会社 CaSR激动剂
WO2010042642A1 (fr) * 2008-10-08 2010-04-15 Amgen Inc. Agents modulateurs des récepteurs de calcium
WO2010104882A1 (fr) 2009-03-10 2010-09-16 Amgen Inc. Procédés de modulation de la motilité des spermatozoïdes
WO2010136037A1 (fr) 2009-05-27 2010-12-02 Leo Pharma A/S Nouveaux composés modulant le récepteur sensible au calcium, et leur utilisation pharmaceutique
WO2010136035A2 (fr) 2009-05-27 2010-12-02 Leo Pharma A/S Composés inédits modulant les récepteurs du calcium et leur utilisation pharmaceutique
EP2588444A1 (fr) 2010-06-30 2013-05-08 Leo Pharma A/S Nouvelle forme polymorphe d'un composé calcimimétique
JP5968880B2 (ja) 2010-06-30 2016-08-10 レオ ファーマ アクティーゼルスカブ カルシウム模倣化合物の新規多形
US20130267516A1 (en) 2010-11-26 2013-10-10 Leo Pharma A/S Substituted cyclopentyl-azines as casr-active compounds
US20130261132A1 (en) 2010-11-26 2013-10-03 Leo Pharma A/S Calcium-sensing receptor-active compounds
US20130245084A1 (en) 2010-11-26 2013-09-19 Leo Pharma A/S Calcium-sensing receptor-active compounds
US20130244995A1 (en) 2010-11-26 2013-09-19 Leo Pharma A/S Calcium-sensing receptor-active compounds
FR2969150B1 (fr) 2010-12-20 2013-07-26 Centre Nat Rech Scient Nouvelles molecules indoliques demontrant des activites antibacteriennes dans une variete de bacteries a gram-negatif et positif dont des bacteries multidrogues-resistantes
AU2012226375B2 (en) 2011-03-10 2017-04-13 Lupin Atlantis Holdings Sa Substituted morpholines as modulators for the calcium sensing receptor
KR20140051846A (ko) 2011-03-18 2014-05-02 루핀 리미티드 칼슘 감지 수용체 조절자로서의 벤조[ｂ][1,4]옥사진 유도체
HUE046172T2 (hu) 2012-02-24 2020-02-28 Lupin Ltd Szubsztituált krománvegyületek mint kalcium-szenzor receptor modulátorok
WO2013136288A1 (fr) 2012-03-16 2013-09-19 Lupin Limited Composés de type 3,4-dihydro-2h-benzo[b] [1,4]oxazine substituée utilisés en tant que modulateurs des récepteurs sensibles au calcium
US9227919B2 (en) 2012-08-27 2016-01-05 Lupin Limited Arylalkylamine compounds as calcium sensing receptor modulators
GB201217330D0 (en) 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders
TW201602062A (zh) 2013-08-12 2016-01-16 魯賓有限公司 取代聯苯基化合物作為鈣敏感受體調節劑
AU2014313835A1 (en) * 2013-08-28 2016-03-03 Lupin Atlantis Holdings Sa Substituted naphthalene compounds as calcium sensing receptor modulators
WO2015162538A1 (fr) 2014-04-21 2015-10-29 Lupin Limited Composés hétérocycliques en tant que modulateurs des récepteurs de détection du calcium pour le traitement de l'hyperparathyroïdie, de l'insuffisance rénale chronique et de la néphropathie chronique
WO2017037616A1 (fr) 2015-08-31 2017-03-09 Lupin Limited Composés d'arylalkylamine comme modulateurs des récepteurs sensibles au calcium
WO2021130779A1 (fr) 2019-12-27 2021-07-01 Lupin Limited Composition pharmaceutique de modulateurs de casr et procédés et utilisations associés
WO2021144814A1 (fr) 2020-01-17 2021-07-22 Lupin Limited Procédés, processus et intermédiaires pour la préparation de composés chromane

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3906099A (en) * 1972-06-08 1975-09-16 Warner Lambert Co 1,2,3,4-Tetra hydro-3-aminomethylisoquinolines in the treatment of mental depression
ES2002416A6 (es) * 1986-10-14 1988-08-01 Consejo Superior Investigacion Procedimiento para la obtencion de derivados acetilenicos y alenicos de 2-aminometil-(1-metilindoles)
ES2010406A6 (es) * 1989-02-16 1989-11-01 Consejo Superior Investigacion Procedimiento para la obtencion de derivados acetilenicos y alenicos de 2-aminometil-(1-metil-indoles).
EP1281702B1 (fr) * 1991-08-23 2005-12-21 Nps Pharmaceuticals, Inc. Composés capables de moduler l'activité du récepteur de calcium
PL183499B1 (pl) * 1994-10-21 2002-06-28 Nps Pharma Inc Związki do modulowania receptorów wapniowych i kompozycje farmaceutyczne
AU4547796A (en) * 1995-02-03 1996-08-21 Sankyo Company Limited Hexahydropyrazinoquinoline derivatives
ATE204738T1 (de) * 1995-10-16 2001-09-15 Procter & Gamble Haarpflegeshampoo
WO2000021910A2 (fr) * 1998-10-14 2000-04-20 Ortho-Mcneil Pharmaceutical, Inc. Cyclopropanes a disubstitution en position 1 et 2
CN1161340C (zh) * 1998-11-30 2004-08-11 先灵公司 为玻连蛋白受体拮抗剂的苯并咪唑化合物
JP2002532465A (ja) 1998-12-16 2002-10-02 バイエル アクチェンゲゼルシャフト インテグリンアンタゴニストとしての新規なビフェニル及びビフェニル−類似化合物
FR2798845B1 (fr) * 1999-09-29 2001-11-23 Oreal Composition de lavage des matieres keratiniques, a base d'un agent tensio-actif detergent, d'un polyorganosiloxane et d'un terpolymere acrylique
FR2800735B1 (fr) 1999-11-09 2002-02-01 Centre Nat Rech Scient Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation

Also Published As

Publication number Publication date
EP1284963A1 (fr) 2003-02-26
WO2001090069A1 (fr) 2001-11-29
EP1284963B1 (fr) 2012-05-09
US20030199497A1 (en) 2003-10-23
US7084167B2 (en) 2006-08-01
FR2809396A1 (fr) 2001-11-30
ATE557002T1 (de) 2012-05-15
FR2809396B1 (fr) 2005-10-14
JP2003534324A (ja) 2003-11-18
WO2001090069B1 (fr) 2002-04-11

Similar Documents

Publication Publication Date Title
AU2001264012A1 (en) Novel calcium receptor active molecules and method for preparing same
AU1400801A (en) Aralkyl-1,2-diamines having calcimimetic activity and preparation mode
TWI255807B (en) Therapeutic agents
AP1822A (en) Substituted pyridinones as modulators of P38 MAP kinase.
AR012593A1 (es) Pirrolopiridinas sustituidas, composicion farmaceutica que las contiene, procedimiento para su preparacion y el uso de las mismas en la manufacturade un medicamento
SE9904176D0 (sv) New use
MY102866A (en) Amide derivatives.
ES2133163T3 (es) Esteres (o tioesteres) del acido n-acilsulfamico y esteres (o tioesteres) del acido n-sulfonilcarbamico como agentes hipercolesterolemicos.
SE9701144D0 (sv) Novel compounds, their use and preparation
HUP0105437A2 (hu) Új malonsavszármazékok, előállításuk és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények
DE60132309D1 (de) Amin-derivate zur behandlung von apoptosis
IL157653A0 (en) Novel amides, preparation and therapeutic use as modulators of ccr-receptor activity
DE60042831D1 (de) Pharmazeutisch aktive sulfonylaminosäurederivate
YU224790A (sh) Aminokarbonil karbamati, sorodni fizostigminu/in postopek za njihovo pripravo in njihova uporaba kot zdravila
HUP0003577A2 (hu) Tetrahidro-gamma-karbolinok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
BR0008776A (pt) Análogos de prostaglandinas fp-seletivosinsaturados c16
DE69501359T2 (de) Verwendung von Phosphatdiestern zur Behandlung von Erkrankungen der Retina
EA200600866A1 (ru) Применение галоидного производного гидроксимовой кислоты для лечения нейродегенеративных заболеваний
SE0203820D0 (sv) chemical compounds
HUP0301553A2 (hu) Gyógyászati készítmények és alkalmazásuk neurológiai rendellenességek kezelésére
SE0203828D0 (sv) Chemical compounds
SE9900190D0 (sv) New compounds
HUP0202647A2 (hu) Új arilalkanoilszármazékok, előállításuk és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények
ATE181503T1 (de) Verwendung von idazoxan und derivaten zur herstellung eines arzneimittels zur behandlung von parkinsonismus und seiner evolution
RU2221786C2 (ru) Производные тетрагидроизохинолиналканола, способы лечения и фармацевтические композиции на их основе